Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Accorda Therapeutics

(ACOR) - Get Report

downgraded at Baird from Outperform to Neutral. $31 price target. Latest Ampyra survey indicates lower projected patient share.

BP

(BP) - Get Report

rated new Hold at Jefferies. It will still take several more months to quantify the final Macondo costs.

Carefusion

(CFN)

downgraded at Goldman to Neutral. Company could be hurt by lower near-term hospital CapEx spending.

ConocoPhillips

(COP) - Get Report

rated new Buy at Jefferies. $75 price target. Asset sales should benefit the company.

Covidien

(COV)

upgraded at Goldman to Buy, Goldman Sachs said. $53 price target. Stock has lagged its peers, but is already pricing in lower surgical volumes.

Fluor

(FLR) - Get Report

rated new Buy at Keybanc. $74 price target. Company has exposure to robust end-market demand.

Foster Wheeler

(FWLT)

rated new Hold at Keybanc. Company lacks near-term catalysts.

TRW Automotive

(TRW)

upgraded at Keybanc from Hold to Buy. $69 price target. Company should benefit from a recovery in demand for autos and commercial vehicles.

This article was written by a staff member of TheStreet.